MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.99
-1.61
-4.40%
After Hours: 34.62 -0.38 -1.07% 17:35 05/07 EDT
OPEN
36.53
PREV CLOSE
36.60
HIGH
37.51
LOW
34.86
VOLUME
1.75M
TURNOVER
--
52 WEEK HIGH
71.25
52 WEEK LOW
33.53
MARKET CAP
4.90B
P/E (TTM)
-31.4941
1D
5D
1M
3M
1Y
5Y
Global SSD Caching Market size 2019 share, industry growth rate, market characterisation, forecast to 2024
May 07, 2021 (The Expresswire) -- Global "Global SSD CachingMarket" (2021-2024) report identifies Sales of Market by regional analysis by product type and...
The Express Wire · 2d ago
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 3d ago
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results
SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...
GlobeNewswire · 3d ago
BRIEF-Adaptive Biotechnologies Reports Q1 2021 Financial Results
reuters.com · 3d ago
CAPROCK Group, Inc. Buys S&P 500 ETF TRUST ETF, Palantir Technologies Inc, C3. ...
GuruFocus News · 04/29 15:38
Earnings Preview: Adaptive Biotechnologies (ADPT) Q1 Earnings Expected to Decline
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/28 17:33
Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
GlobeNewswire · 04/27 20:18
Andreas Halvorsen Takes Stake in Mudrick Capital Acquisition Following Merger Announcement
GuruFocus News · 04/21 15:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADPT. Analyze the recent business situations of Adaptive Biotechnologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADPT stock price target is 62.00 with a high estimate of 67.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 324
Institutional Holdings: 114.47M
% Owned: 81.76%
Shares Outstanding: 140.00M
TypeInstitutionsShares
Increased
83
10.25M
New
59
1.70M
Decreased
80
7.00M
Sold Out
15
1.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
Chad Robins
President
Julie Rubinstein
Co-Founder/Chief Scientific Officer
Harlan Robins
Chief Financial Officer
Chad Cohen
Senior Vice President/General Manager
.. Willis
Chief Operating Officer
Mark Adams
Chief Human Resource Officer
Francis Lo
Senior Vice President/General Counsel
Stacy Taylor
Senior Vice President
Sharon Benzeno
Senior Vice President
Nancy Hill
Senior Vice President
Jyoti Palaniappan
Senior Vice President
Charles Snag
Other
Lance Baldo
Other
Sean Nolan
Lead Director/Independent Director
Peter Neupert
Independent Director
Kevin Conroy
Independent Director
Michelle Griffin
Independent Director
Robert Hershberg
Independent Director
Katey Owen
Independent Director
Michael Pellini
Independent Director
Leslie Trigg
No Data
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.